Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 4, 2003 - Issue 4
Submit an article Journal homepage
87
Views
13
CrossRef citations to date
0
Altmetric
Review

New developments in migraine prophylaxis

Marcelo E Bigal Department of Neurology, Albert Einstein College of Medicine, 1125 Morris Park Avenue, office 334 A, Bronx, New York, USA
,
Abouch V Krymchantowski Department of Neurology, Albert Einstein College of Medicine, 1125 Morris Park Avenue, office 334 A, Bronx, New York, USA
&
Alan M Rapoport Department of Neurology, Albert Einstein College of Medicine, 1125 Morris Park Avenue, office 334 A, Bronx, New York, USA
Pages 433-443 | Published online: 02 Mar 2005

Bibliography

  • SCHER AI, STEWART WF, LIPTON RB:Migraine and headache: a meta-analytic approach. In: Epidemiology of pain. Crombie IK (Ed.), IASP press, Seattle, USA (1999):159–170.
  • •Reviews the prevalence and impact of migraine.
  • STEWART WF, SHECHTER A, LIPTON RB: Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology (1994) 44\(Suppl. 4):524–539.
  • LIPTON RB, STEWART WF: Prevalence and impact of migraine. Neural Clin. (1997) 15:1–13.
  • BLUMENTHAL HJ, RAP OPORT AM: The clinical spectrum of migraine. In: The Medical Clinics of North America vol. 85. Mathew NT (Ed.), WB Saunders, Philadelphia, USA (2001):897–909.
  • •Describes in detail all migraine subtypes.
  • WELCH KM, D'ANDREA G,TEPLEY N etal.: The concept of migraine as a state of central neuronal hyperexcitability. Neural Clin (1990) 8:817–828.
  • •Discusses migraine pathophysiology and the importance of implications in understanding the new drugs.
  • WELCH KM, BARKLEY GL, TEPLEY N et al.: Central neurogenic mechanisms of migraine. Neurology (1993) 43:S21–S25.
  • LAURITZEN M: Pathophysiology of the migraine aura. The spreading depression theory. Brain (1994) 117:199–210.
  • LANCE JW, LAMBERT GA,GOADSBY PJ, DUCKWORTH JW: Brainstem influences on the cephalic circulation: experimental data from cat and monkey of relevance to the mechanism of migraine. Headache (1983) 23:258–265.
  • WELCH KM, NAGESH V, AURORA SK, GELMAN N: Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache (2001) 41:629–637.
  • OPHOFF RA, TENWINDT GM, VERGOUVE MN: Familial hemiplegicmigraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNLA4. Cell (1996) 87:543–552.
  • WELCH KM, RAMADAN NM: Mitochondria, magnesium and migraine. Neural Li. (1995) 134:9–14.
  • MATHEW NT, SILBERSTEIN SD: Anticonvulsants in migraine prophylaxis. In: Drug Treatment of Migraine and Other Headaches. Monogr. Chit. Neurosci. Diener HC (Ed.), S Karger AG, Basel, Switzerland (2000):288–298.
  • •A thorough review of AEDs in migraine prophylaxis.
  • MATHEW NT, SAPER JR, SILBERSTEIN SD et al: Migraine prophylaxis with divalproex. Arch. Neural (1995) 52:281–286.
  • SILBERSTEIN SD, COLLINS SD: Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term safety of depakote in headache prophylaxis study group. Headache (1999) 39:633–643.
  • CUTRER FM, LIMMROTH V, AYATA G, MOSKOWITZ MA: Valproate 441 Expert Op/n. Pharmacother. (2003) 4(4)reduces C-Fos expression in trigeminal nucleus caudalis (TNC) after noxious meningeal stimulation. Cephalalgia (1995) 15\(Suppl. 14):S96 (Abstract).
  • CUTRER FM, MOSKOWITZ M: Actions of valproate and neurosteroids in a model of trigeminal pain. Headache (1996) 36:579–585.
  • SILBERSTEIN SD, GOADSBY PJ: Migraine: preventive treatment. Cephalalgia (2002) 22:491–512.
  • •Updated review of standard preventive treatments.
  • HERING R, KURITZKY A:Sodium valproate in the prophylactictreatment of migraine: a double-blind study versus placebo. Cephalalgia (1992) 12:81–84.
  • JENSEN R, BRINK T, OLESEN J: Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology (1994) 44:647–651.
  • KLAPPER J: Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia (1997) 17:103–108.
  • KANIECKI RG: A comparative study of propranolol and divalproex sodium in the prophylaxis of migraine. Arch. Neural (1997) 54:1141–1144.
  • FREITAG FG, COLLINS SD,CARLSON HA etal.: A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology (2002) 58:1652–1569.
  • PELLOCH JM, WILLMORE LJ: Rational guide to routine blood monitoring in patients receiving anti-epileptic drugs. Neurology (1991) 41:961–964.
  • DRIEFUSS FE, SANTILLI N, LANGER DH, SWEENEY KP MOLINE KA, MENANDER KB: Valproic acid hepatic fatalities: a retrospective review. Neurology (1987) 37:379–385.
  • VAINIONPAA UK, RATTYA J, KNIP M et al.: Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann. Neural. (1999) 45:444–450.
  • SILBERSTEIN SD: Divalproex sodium in headache - literature review and clinical guidelines. Headache (1996) 36:547–555.
  • MATHEW NT, SILBERSTEIN SD: Anticonvulsants in migraine prophylaxis. In: Drug Treatment of Miine and Other Headaches. Diener HC (Ed.), S Karger AG, Basel, Switzerland (2000) 17:295.
  • SHACHTER SC: Epilepsy. Neural Clirr. (2001) 19:57–78.
  • GRAM L: Pharmacokinetics of new antiepileptic drugs. Epilepsia (1996) 37\(Suppl. 6):S12–S16.
  • TAYLOR CP, GEE NS, SU TZ, et al.: A summary of mechanistic pharmacology of gabapentin. Epilepsy Res. (1998) 29:233–249.
  • MATHEW NT: Gabapentin in migraine prophylaxis. Cephalalgia (1996) 16:367 (Abstract).
  • MATHEW NT, RAP OPORT A, SAPER J, etal.: Efficacy of gabapentin in migraine prophylaxis. Headache (2001) 41:119–128.
  • DODGSON SJ, SHANK RP MARYANOFF BE: Topiramate as an inhibitor of carbonic anhydrase isoenzymes Epilepsia (2000) 41:35–39.
  • SIGEL E: Functional modulation of ligand-gated GABAA and NMDA receptor channels by phosphorilation. Receptor Signal Trarisduct. Res. (1995) 15:325–332.
  • GIBBS JW, SOMBATI S,DELORENZO RJ, COULTER DA: Cellular actions of topiramate: blockade of kainite-evoked inward currents in cultured hippocampal neurons. Epilepsia (2000) 41:S10–S16.
  • SHUAIB A, AHMED E MURATOGLU M, KOCHANSKI P: Topiramate in migraine prophylaxis: a pilot study. Cephalalgia (1999) 19:379-380 (Abstract).
  • KRUSZ JC, SCOTT V: Topiramate in the treatment of chronic migraine and other headaches. Headache (1999) 39:363 (Abstract).
  • EDWARDS KR, GLANTZ MJ, SHEA P, NORTON JA, CROSS N: Topiramate for migraine prophylaxis: a double-blind, randomized, placebo-controlled study. Headache (2000) 40:407 (Abstract).
  • POTTER DL, HART DE, CALDER CS, STOREY JR: A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine. Neurology (2000) 54\(Suppl. 3):A15 (Abstract).
  • SILBERSTEIN S, KARIN R, JORDAN D, HULIHAN J: Treatment effect for topiramate in migraine prophylaxis: utility of repeated measures and weighted regression analyses. Cephalalgia (2002) 22:610 (Abstract).
  • EDWARDS KR, KAMIN M: The beneficial effect of slowing the initialtitration rate of topiramate. Neurology (1997) 48:A39 (Abstract).
  • DRAKE JR ME, KAY AM, KNAPP MS, GREATHOUSE NI: An open-label trial of tiagabine for migraine prophylaxis. Headache (1999) 39:352 (Abstract).
  • FREITAG FG, DIAMOND S,DIAMOND ML, URBAN GJ, PEPPER B, MOORE K: The prophylaxis of migraine with the GABA-agonist, tiagabine: a clinical report. Headache (1999) 39:354 (Abstract).
  • KRUSZ JC: Levetiracetam as prophylaxis for resistant headaches. Cephalalgia (2001) 21:373 (Abstract).
  • DRAKE ME, GREATHOUSE NI, ARMENTBRIGHT AD, RENNER JB: Levetiracetam for preventive treatment of migraine. Cephalalgia (2001) 21:373 (Abstract).
  • PRICE MJ: Levetiracetam: preventive therapy in migraine. Headache (2002) 42:455-456 (Abstract).
  • DRAKE ME, GREATHOUSE NI, ARMENTBRIGHT AD, RENNER JB: Preventive treatment of migraine with zonisamide. Cephalalgia (2001) 21:374 (Abstract).
  • KRUSZ JC: Zonisamide in the treatment of headache disorders. Cephalalgia (2001) 21:374-375 (Abstract).
  • SCHRADER H, STOVNER LJ, HELDE G, SAND T, BOVIM G: Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomized, placebo-controlled, crossover study. Br Med. J. (2001) 322:19–22.
  • SKID GEL RA, ERDOS EG: The broad substrate specificity of human angiotensin converting enzyme. Clirr. Exp. Hyperteris. (1987) 9:243–259.
  • PARANTAINEN J, VAPAATALO H, HOKKANEN E: Clinical aspects of prostaglandins and leukotrienes (LT) in migraine. Cephalalgia (1986) 6\(Suppl. 4):S95–S101.
  • SHEFTELL F, RAPOPORT A, WEEKS R, WALKER PA, GAMMERMAN I, BASKIN S: Montelukast in the prophylaxis of migraine: a potential for leukotriene modifiers. Headache (2000) 40:158–163.
  • BRANDES JL, SCHUHL AL,FARMER MV, MALBEQ W, VISSER W: Preventive treatment of migraine headache with montelukast. Headache (2002) 42:451 (Abstract).
  • SMALL JG, HIRSCH SR,ARVANITIS LA, MILLER BG, LINK CG: Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch. Gen. Psychiatry (1997) 54:549–557.
  • BRANDES JL, ROBERSON SC, PEARLMAN SH, ABU-SHAKRA S: Quetiapine for migraine prophylaxis. Headache (2002) 42:450–451.
  • SAPER JR, LAKE AE, CANTRELL DT, WINNER PK, WHITE JR: Chronic daily headache prophylaxis with tizanidine: a double blind, placebo controlled, multicenter outcome study. Headache (2002) 42:470–482.
  • ZAIMIS E, HANINGTON E: A possible pharmacological approach to migraine. Lancet (1969) 2:298–300.
  • KRUSZ JC, BELANGER J, MILLS C: Tizanidine: a novel effective agent for the treatment of chronic headaches. Headache (2000) 11:41–45.
  • SIMPSOM LL: The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev (1981) 33:155–188.
  • VOLKNANDT W: Commentary: the synaptic vesicle and its targets. Neuroscience (1995) 64:277–300.
  • BINDER W, BRIN MF, BLITZER A, SCHOENROTCK L, DIAMOND B: Botulinum toxin type A (BTX-A) for migraine: an open label assessment. Mov. Disord. (1998) 13\(Suppl. 2):S241 (Abstract).
  • SILBERSTEIN SD, MATHEW NT, SAPER J, JENKINS S: Botulinum toxin type A as a migraine preventive treatment. Headache (2000) 40:445–450.
  • MATHEW NT, KAILASAN J, MEADORS L: 'Disease modification' in chronic migraine with botulinum toxin type A: a long term experience. Headache (2002) 42:254.
  • EATON J: Butterbur, herbal help for migraine. Nat. Pharm. (1998) 2:23–24.
  • LIPTON RB, GOBEL H, WILKS K, MAUSKOP A: Efficay of petasites (an extract from Petasites rhizome) 50 and 75 mg for prophylaxis of migraine: results of a randomized, double-blind, placebo controlled study. Neurology (2002) 58:A472.
  • LIN H, CHIEN CH, LIN YL et al: Inhibition of testosterone secretion by S-petasin in rat testicular interstitial cells. Chin. Physiol (2000) 43:99–103.
  • STEGELMEIER BL, EDGAR JA, COLEGATE SM etal.: Pyrrolizidine alkaloid plants, metabolism and toxicity. Nat. Toxins (1999) 8:95–116.
  • DOWSON DI, LEWITH GT,MACHIN D: The effects of acupuncture versus placebo on the treatment of headache. Pain (1985) 21:35–42.
  • ALLAIS G, DE LORENZO C, QUIRICO P et al.: Acupuncture in the prophylactic treatment of migraine without aura: a comparison with flunarizine. Headache (2002) 42:855–861.
  • KRYMCHANTOWSKI AV, BIGAL ME, MOREIRA PF: New and emerging prophylactic agents for migraine. CNS Drugs (2002) 16:611–634.

Websites

  • http://www.aan.corniprofessionals/practice/ pdfs/g10090.pdfRAMADAN MN, SILBERSTEIN SD, FREITAG FG, GILBERT TT, FRISHBERG GM: Pharmacological management for prevention of migraine.
  • •Presents the US Headache Consortium guidelines regarding the preventive treatment of migraine.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.